PauseRX review
PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and…
Est. first month
$199/mo
- Semaglutide
- $199/mo
- Tirzepatide
- From $249/mo (starting dose, compounded)
- Coverage
- Coverage not published
- Brand-name
- Yes
The Value Score card
PauseRX scored on our six published factors. See the methodology.
Why it's a deal
- Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
- Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
- Publishes the FDA compounded-medication disclaimer
- Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
- Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation
Read the fine print
- States served not listed — site claims nationwide, but you must contact support to confirm availability
- Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
- No named medical director (Beluga Health is the network, not a named MD)
- LegitScript certification number not shown — badge only, so no direct lookup
- Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed
The bottom line
Best for: Shoppers who want explicit 503A pharmacy and physician-network disclosure. PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and…
Ranked #180 of 395 programs we track — see our #1 deal, CoreAge Rx, for comparison.
Compare with other deals
The programs scoring closest to PauseRX, out of 394 others we track.
Shopping PauseRX against a specific rival? We put it head to head with our top-scoring pick on CoreAge Rx vs PauseRX, and every program that undercuts or outscores it is ranked on the PauseRX alternatives board.
- From $133/mo (starting dose, compounded)LumiMeds— Telehealth provider with flat-rate compounded GLP-1 pricing on a 3-month plan.73/100
- From $125/mo (3-month plan, compounded)Nova MD— Nova MD is a telehealth platform offering compounded semaglutide and tirzepatide on 1-month and 3-month plans, with an uncommon explicit microdose program for both molecules.73/100
- From $139/mo (compounded)NuvaHealth— NuvaHealth (nuvahealth.org) is a LegitScript-certified compounded GLP-1 telehealth platform offering compounded semaglutide starting at $159 first-month and compounded tirzepatide starting at $259 first-month.73/100
- From $299/mo (compounded)RestorLife Med— RestorLife Med is a physician-guided GLP-1 telehealth practice (founder Dr.73/100
- From $135/mo (starting dose, compounded)Somi Health— Somi Health is a telehealth weight-loss provider offering compounded GLP-1 medications - compounded semaglutide and tirzepatide injections plus an oral semaglutide tablet.73/100
- From $199/mo (all doses, compounded)TOM Weight Loss— Solo-physician DTC telemedicine clinic in Texas + Utah operated by Dr.73/100
More programs we track (24)
- #1 CoreAge Rx93
- #2 Ondra Health92
- #4 Vitara RX91
- #5 Gimme Care91
- #7 Alan Meds90
- #3 Trimi Health89
- #10 Precision Telemed89
- #11 bmiMD89
- #12 Care Clinics89
- #6 Oak88
- #16 Live Vital88
- #17 AmberHealth88
- #18 Fresh Day Meds88
- #8 Sesame Care87
- #9 Strut Health87
- #22 EverSlim87
- #23 NewSelf87
- #24 Vaylen87
- #25 Mint Med87
- #13 HealthRX86
- #14 RxSpan MD86
- #15 Sprout Health86
- #28 Bionomy Health86
- #29 BetterMe Rx86
364 more are reviewed too — see every GLP-1 program we track, ranked.
Pricing and coverage on this page were read from PauseRX's own website on ; the Value Score is our editorial judgment per the methodology. “% vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on PauseRX's site. Not medical advice; see our disclosure.